High-dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: An Asian series

Journal of Dermatology

Volumn 32, Issue 1, 2005, Pages 1-6

  Tan, Audrey W ^a   Thong, Bernard Y ^b   Yip, Leonard W ^b   Chng, Hiok Hee ^b   Ng, See Ket ^a  

^a NATIONAL SKIN CENTRE   (Singapore)

^b TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

Drug hypersensitivity; Immunotherapy; Stevens Johnson syndrome

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; PREDNISOLONE;

ADULT; AGED; ARTICLE; ASIA; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LENGTH OF STAY; MALE; RETROSPECTIVE STUDY; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SURVIVAL RATE; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME;

EID: 14644424631     PISSN: 03852407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2005.tb00704.x     Document Type: Article

References (13)

1. Paul C, Wolkenstein P, Adle H, et al: Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis, Br J Dermatol, 134: 710-714, 1996.
2. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC: Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme, Arch Dermatol, 129: 92-96, 1993.
3. Revuz J, Penso D, Roujeau JC, et al: Toxic epidermal necrolysis: Clinical findings and prognosis factors in 87 patients, Arch Dermatol, 123: 1160-1165, 1987.
4. Viard I, Wehrli P, Bullani R, et al: Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin, Science, 282: 490-493, 1998.
5. Abe R, Shimizu T, Shibaki A, Nakamura H, Watanabe H, Shimizu H: Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble ligand, Am J Pathol, 162: 1515-1520, 2003.
6. Nassif A, Bensussan A, Dorothee G, et al: Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis, J Invest Dermatol, 118: 728-733, 2002.
7. Posadas SJ, Padial A, Torres MJ, et al: Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity, J Allergy Clin Immunol, 109: 155-161, 2002.
8. Mayorga C, Torres MJ, Corzo JL, et al: Improvement of toxic epidermal necrolysis after the early administration of a single high dose of intravenous immunoglobulin, Ann Allergy Asthma Immunol, 91: 86-91, 2003.
9. Bachot N, Revuz J, Roujeau JC: Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression, Arch Dermatol, 139: 33-36, 2003.
10. Schifferli J, Leski M, Favre H, Imbach P, Nydegger U, Davies K: High-dose intravenous IgG treatment and renal function, Lancet, 337: 45-48, 1991.
11. Prins C, Kerdel FA, Padilla RS, et al: TEN-IVIG study group. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins, Arch Dermatol, 139: 26-32, 2003.
12. Trent JT, Kirsner R, Romanelli P, Kerdel FA: Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami experience, Arch Dermatol, 139: 39-43, 2003.
13. Bachot N, Roujeau JC: Intravenous immunoglobulins in the treatment of severe drug eruptions, Curr Opin Allergy Clin Immunol, 3: 269-274, 2003.